

# Shubham Maurya

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3479406/publications.pdf>

Version: 2024-02-01

8  
papers

135  
citations

1478505

6  
h-index

1720034

7  
g-index

8  
all docs

8  
docs citations

8  
times ranked

122  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of Adeno-associated virus-based vector-mediated gene therapy—impact of vector dose. <i>Cancer Gene Therapy</i> , 2022, 29, 1305-1306.	4.6	13
2	Gene Therapy: Contest between Adeno-Associated Virus and Host Cells and the Impact of UFMylation. <i>Molecular Pharmaceutics</i> , 2020, 17, 3649-3653.	4.6	1
3	Improved ocular gene transfer with a Neddylaton-site modified AAV-RPE65 vector in rd12 mice. <i>Eye</i> , 2020, 34, 1313-1315.	2.1	4
4	Exosome-associated SUMOylation mutant AAV demonstrates improved ocular gene transfer efficiency in vivo. <i>Virus Research</i> , 2020, 283, 197966.	2.2	12
5	AAV6 Vexosomes Mediate Robust Suicide Gene Delivery in a Murine Model of Hepatocellular Carcinoma. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 17, 497-504.	4.1	21
6	Post-translational modifications in capsid proteins of recombinant adeno-associated virus (<sc>AAV</sc>) 1&rh10 serotypes. <i>FEBS Journal</i> , 2019, 286, 4964-4981.	4.7	53
7	Molecular Engineering of Adeno-Associated Virus Capsid Improves Its Therapeutic Gene Transfer in Murine Models of Hemophilia and Retinal Degeneration. <i>Molecular Pharmaceutics</i> , 2019, 16, 4738-4750.	4.6	15
8	Rational Engineering and Preclinical Evaluation of Neddylaton and SUMOylation Site Modified Adeno-Associated Virus Vectors in Murine Models of Hemophilia B and Leber Congenital Amaurosis. <i>Human Gene Therapy</i> , 2019, 30, 1461-1476.	2.7	16